In the trial, this formulation was compared to intravenous pertuzumab plus trastuzumab for the neoadjuvant/adjuvant treatment of HER2-positive early breast cancer in terms of pharmacokinetics, efficacy, and safety. The gene discussed is ERBB2; the disease is breast carcinoma.